Toleris Biotherapeutics develops highly effective first-in-class targeted biotherapeutics (AIM Biologicals) that use a physiological tolerance mechanism to treat autoimmune diseases.
Toleris was founded in January 2024, is led by an experienced team of scientists and entrepreneurs and is located in Würzburg, Germany. We are actively looking for investors and partners interested in exploring the therapeutic potential of our award-winning platform technology.